Years after failed IPO attempts, Alzheon raises $50M round for Alzheimer’s study

After Alzheon’s two attempts at going public came up empty, the biotech has raised $50 million in series D funding from undisclosed investors, giving it runway for a Phase III trial in a subpopulation of patients with Alzheimer’s disease.

The investment complements a five-year, $47 million grant from the National Institute on Aging announced in August 2020 to support the APOLLOE4 trial of valiltramiprosate (ALZ-801) in early Alzheimer’s patients homozygous for the APOE4. Alzheon Inc. said in June 2021 that it had dosed the first patient in the Phase III study...